The DOI matches its Crossref record; 316 of the 316 references it cites were found in a registry or an index.
Natural products: An evolving role in future drug discovery
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–316 of 316
PKC inhibition and diabetic microvascular complications
Clarke, M., & Dodson, P. M. (2007) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2007.09.007 · Cited by 85
Eyerman, D. J., & Yamamoto, B. K. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.072264 · Cited by 85
Mokhtari, M. J., Motamed, N., & Shokrgozar, M. A. (2008) · Cell Biology International · doi:10.1016/j.cellbi.2008.03.019 · Cited by 84
Srougi, M. C., Reinicke, K. E., Dong, Y., Bey, E. A., & Boothman, D. A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0935 · Cited by 82
Aretz, W., Meiwes, J., SEIBERT, G., Vobis, G., & Wink, J. M. (2000) · The Journal of Antibiotics · doi:10.7164/antibiotics.53.807 · Cited by 81
Ajulemic acid: A novel cannabinoid produces analgesia without a “high”
BURSTEIN, S. H., Karst, M., Schneider, U., & Zurier, R. B. (2004) · Life Sciences · doi:10.1016/j.lfs.2004.04.010 · Cited by 81
Yuan, C. (2007) · Annals of Pharmacotherapy · doi:10.1345/aph.1k009 · Cited by 80
Antitubulin agents for the treatment of cancer – a medicinal chemistry update
Mahindroo, N., Liou, J., Chang, J., & Hsieh, H. (2006) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.16.5.647 · Cited by 79
Sader, H. S., Fritsche, T. R., & Jones, R. N. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01351-07 · Cited by 79
Barnett, A. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.15.2593 · Cited by 79
Shionoya, M., Jimbo, T., Kitagawa, M., Soga, T., & Tohgo, A. (2003) · Cancer Science · doi:10.1111/j.1349-7006.2003.tb01465.x · Cited by 77
Using Natural Product Inhibitors to Validate Hsp90 as a Molecular Target in Cancer
Neckers, L. (2006) · Current Topics in Medicinal Chemistry · doi:10.2174/156802606777811979 · Cited by 77
Martin, D. E., Blum, R. A., Wilton, J. H., Doto, J., Galbraith, H., Burgess, G. L., Smith, P. C., & Ballow, C. H. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01391-06 · Cited by 77
Wecke, T., Zühlke, D., Mäder, U., Jordan, S., Voigt, B., Pelzer, S., Labischinski, H., Homuth, G., Hecker, M., & Mascher, T. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01046-08 · Cited by 77
Bush, K., Heep, M., Macielag, M. J., & Noel, G. J. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.4.419 · Cited by 75
Quintieri, L., Geroni, C., Fantin, M., Battaglia, R., Rosato, A., Speed, W., Zanovello, P., & Floreani, M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1845 · Cited by 74
A Phase I Trial of Intranasal Moli1901 for Cystic Fibrosis
Zeitlin, P. L., Boyle, M., Guggino, W. B., & Molina, L. (2004) · CHEST Journal · doi:10.1378/chest.125.1.143 · Cited by 73
Kim, S., Kim, S., Kim, Y., Jeon, Y. T., Lee, S., & Song, Y. S. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.04899.x · Cited by 72
D’Alessandro, S., Gelati, M., Basilico, N., Parati, E. A., Haynes, R. K., & Taramelli, D. (2007) · Toxicology · doi:10.1016/j.tox.2007.08.084 · Cited by 72
Coleman, B. R., Ratcliffe, R. H., Oguntayo, S., Shi, X., Doctor, B. P., Gordon, R. K., & Nambiar, M. P. (2008) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2008.05.023 · Cited by 72
Kem, W. R., Soti, F. S., Wildeboer, K. M., LeFrancois, S., MacDougall, K., Wei, D., Chou, K., & Arias, H. R. (2006) · Marine Drugs · doi:10.3390/md403255 · Cited by 72
Robertson, G. T., Bonventre, E. J., Doyle, T. B., Du, Q., Duncan, L. R., Morris, T. W., Roche, E. D., Yan, D., & Lynch, A. S. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01649-07 · Cited by 72
Tigecycline: A Novel Broad-Spectrum Antimicrobial
Slover, C. M., Rodvold, K. A., & Danziger, L. H. (2007) · Annals of Pharmacotherapy · doi:10.1345/aph.1h543 · Cited by 72
Daum, R. S., Kar, S., & Kirkpatrick, P. J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2442 · Cited by 72
Molecular pharmacology and antitumor activity of Zalypsis® in several human cancer cell lines
Martínez-Leal, J. F., García-Hernández, V., Moneo, V., Domingo, A., Bueren‐Calabuig, J. A., Negri, A., Gago, F., Guillen-Navarro, M. J., Avilés, P., Cuevas, C., et al. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.04.003 · Cited by 71
Jones, R. J., Hawkins, R. E., Eatock, M. M., Ferry, D. R., Eskens, F. A. L. M., Wilke, H., & Evans, T. R. J. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0486-8 · Cited by 71
Structurally simplified macrolactone analogues of halichondrin B
Seletsky, B. M., Wang, Y., Hawkins, L. D., Palme, M. H., Habgood, G. J., DiPietro, L., Towle, M. J., Salvato, K. A., Wels, B. F., Aalfs, K. K., et al. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.08.068 · Cited by 71
Woo, S., Gardner, E. R., Chen, X., Ockers, S. B., Baum, C. E., Sissung, T. M., Price, D. K., Frye, R., Piekarz, R., Bates, S. E., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1215 · Cited by 71
Sourcing a chemical succession for cyclosporin from parasites and human pathogens
PRITCHARD, D. I. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03395-7 · Cited by 69
Semi-synthetic glycopeptide antibacterials
Judice, J. K., & Pace, J. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2003.08.067 · Cited by 68
Mita, A. C., Hammond, L. A., Bonate, P. L., Weiss, G. R., McCreery, H., Syed, S. K., Garrison, M. A., Chu, Q. S.-C., Bono, J. S. D., Jones, C. B., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0179 · Cited by 68
Kim, D., Na, H.-K., Oh, T. Y., Kim, W. B., & Surh, Y. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.04.027 · Cited by 67
Lobelane decreases methamphetamine self-administration in rats
Neugebauer, N. M., Harrod, S. B., Stairs, D. J., Crooks, P. A., Dwoskin, L. P., & Bardo, M. T. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.06.003 · Cited by 67
Ramoplanin: A Lipoglycodepsipeptide Antibiotic
Farver, D., Hedge, D. D., & Lee, S. C. (2005) · Annals of Pharmacotherapy · doi:10.1345/aph.1e397 · Cited by 67
Ersvær, E., Kittang, A. O., Hampson, P., Sand, K. E., Gjertsen, B. T., Lord, J. M., & Bruserud, Ø. (2010) · Toxins · doi:10.3390/toxins2010174 · Cited by 66
MAC-321, a novel taxane with greater efficacy than paclitaxel and docetaxel in vitro and in vivo.
Sampath, D., Discafani, C. M., Loganzo, F., Beyer, C. F., Liu, H., Tan, X., Musto, S., Annable, T., Gallagher, P. A., Rios, C., et al. (2003) · PubMed · Cited by 65
Zheng, G., Dwoskin, L. P., Deaciuc, A. G., Norrholm, S. D., & Crooks, P. A. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0501228 · Cited by 63
Brostallicin, a novel anticancer agent whose activity is enhanced upon binding to glutathione.
Geroni, C., Marchini, S., Cozzi, P., Galliera, E., Ragg, E. M., Colombo, T., Battaglia, R., Howard, M., D’Incalci, M., & Broggini, M. (2002) · PubMed · Cited by 62
Use of cethromycin, a new ketolide, for treatment of community-acquired respiratory infections
Hammerschlag, M. R., & Sharma, R. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.3.387 · Cited by 62
Distamycin A and tallimustine inhibit TBP binding and basal in vitro transcription
Bellorini, M., Moncollin, V., D’lncalci, M., Mongelli, N., & Mantovani, R. (1995) · Nucleic Acids Research · doi:10.1093/nar/23.10.1657 · Cited by 62
Robertson, G. T., Bonventre, E. J., Doyle, T. B., Du, Q., Duncan, L. R., Morris, T. W., Roche, E. D., Yan, D., & Lynch, A. S. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01651-07 · Cited by 62
Joy, S. V., Scates, A. C., Bearelly, S., Dar, M. S., Taulien, C. A., Goebel, J. A., & Cooney, M. J. (2005) · Annals of Pharmacotherapy · doi:10.1345/aph.1e572 · Cited by 60
Bedin, M., Gaben, A., Saucier, C., & Mešter, J. (2004) · International Journal of Cancer · doi:10.1002/ijc.20010 · Cited by 59
Gourdeau, H., McAlpine, J. B., Ranger, M., Simard, B., Berger, F. R., Beaudry, F., & Falardeau, P. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0544-2 · Cited by 58
Novel Pharmacological Approaches for Treating Tobacco Dependence and Withdrawal: Current Status
Buchhalter, A. R., Fant, R. V., & Henningfield, J. E. (2008) · Drugs · doi:10.2165/00003495-200868080-00005 · Cited by 57
Provinciali, M., Papalini, F., Orlando, F., Pierpaoli, S., Donnini, A., Morazzoni, P., Riva, A., & Smorlesi, A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2601 · Cited by 57
Digoxin comes from Digitalis lanata
Hollman, A. (1996) · BMJ · doi:10.1136/bmj.312.7035.912 · Cited by 56
The mechanism of action of Kahalalide F: Variable cell permeability in human hepatoma cell lines
Sewell, J. M., Mayer, I., Langdon, S. P., Smyth, J. F., Jodrell, D. I., & Guichard, S. M. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.04.015 · Cited by 56
Retaspimycin hydrochloride (IPI-504): a novel heat shock protein inhibitor as an anticancer agent
Hanson, B., & Vesole, D. H. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903158934 · Cited by 56
Appetite Suppression and Weight Reduction by a Centrally Active Aminosterol
Ahima, R. S., Patel, H. R., Takahashi, N., Qi, Y., Hileman, S. M., & ZASLOFF, M. A. (2002) · Diabetes · doi:10.2337/diabetes.51.7.2099 · Cited by 56
Phase I/II clinical safety studies of terameprocol vaginal ointment
Khanna, N., Dalby, R. N., Tan, M., Arnold, S. J., Stern, J., & Frazer, N. (2007) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.08.074 · Cited by 55
Echinocandins in the management of invasive fungal infections, part 2
Morris, M. I., & Villmann, M. (2006) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp050464.p2 · Cited by 55
Ray, A., Okouneva, T., Manna, T. K., Miller, H. P., Schmid, S. M., Arthaud, L. E., Ludueña, R. F., Jordan, M. A., & Wilson, L. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3065 · Cited by 55
A novel antifungal anthraquinone from seeds of Aegle marmelos Correa (family Rutaceae)
Mishra, B. B., Kishore, N., Tiwari, V. K., Singh, D. D., & Tripathi, V. (2009) · Fitoterapia · doi:10.1016/j.fitote.2009.08.009 · Cited by 53
Self-citationGerber, M., & Ackermann, G. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.4.547 · Cited by 51
Morphine‐6‐glucuronide (M6G) for postoperative pain relief
Dahan, A., van Dorp, E., Smith, T., & Yassen, A. (2007) · European Journal of Pain · doi:10.1016/j.ejpain.2007.07.009 · Cited by 50
Current Status and Future of Antifungal Therapy for Systemic Mycoses
Nosanchuk, J. D. (2006) · Recent Patents on Anti-Infective Drug Discovery · doi:10.2174/157489106775244109 · Cited by 50
Blick, S. K. A., & Keating, G. M. (2007) · Pediatric Drugs · doi:10.2165/00148581-200709020-00007 · Cited by 50
Steet, R., Chung, S., Lee, W., Pine, C. W., Do, H., & Kornfeld, S. A. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.12.015 · Cited by 49
Emerging echinocandins for treatment of invasive fungal infections
Turner, M., Drew, R. H., & Perfect, J. R. (2006) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.11.2.231 · Cited by 49
Dose‐ and Time‐Dependent Pharmacokinetics of Midostaurin in Patients With Diabetes Mellitus
Wang, Y., Yin, O. Q. P., Gräf, P., Kisicki, J. C., & SCHRAN, H. F. (2008) · The Journal of Clinical Pharmacology · doi:10.1177/0091270008318006 · Cited by 48
Telavancin: a novel lipoglycopeptide for serious Gram-positive infections
Laohavaleeson, S., Kuti, J. L., & Nicolau, D. P. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.3.347 · Cited by 48
Elliott, P. J., Walpole, S., Morelli, L., Lambert, P., Lunsmann, W., Westphal, C. H., & Lavu, S. (2009) · Drugs of the Future · doi:10.1358/dof.2009.034.04.1360696 · Cited by 48
Fritsche, T. R., Rhomberg, P. R., Sader, H. S., et al. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01475-07 · Cited by 48
ヨモギから誘導した薬物学的活性フラボンであるユーパチリンは、ヒト骨髄球白血病細胞にアポトーシスを誘発する | 文献情報 | J-GLOBAL 科学技術総合リンクセンター
H-J, S., & Y-J, S. (2001) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · Cited by 48
Review of dalbavancin, a novel semisynthetic lipoglycopeptide
Kim, A., Kuti, J. L., & Nicolau, D. P. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.5.717 · Cited by 47
Proceedings of the First International Conference on PEP005
Ogbourne, S. M., Hampson, P., Lord, J. M., Parsons, P. G., de Witte, P. A. M., & Suhrbier, A. (2007) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e3280149ec5 · Cited by 47
Development potential of rifalazil
Rothstein, D. M., Hartman, A. D., Cynamon, M. H., et al. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.2.255 · Cited by 47
Chen, Y., & LaCasce, A. S. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.6.939 · Cited by 47
The potential of DMXAA (ASA404) in combination with docetaxel in advanced prostate cancer
McKeage, M. J. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.1.23 · Cited by 45
Wihler, C., Schäfer, S., Schmid, K., Deemer, E. K., Münch, G. W., Bleich, M., Busch, A. E., Dingermann, T., Somoza, V., Baynes, J., et al. (2005) · Diabetologia · doi:10.1007/s00125-005-1837-9 · Cited by 44
Wallace, A. F., LaRosa, D. F., Kapoor, V., Sun, J., Cheng, G., Jassar, A. S., Blouin, A., Ching, L., & Albelda, S. Μ. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3757 · Cited by 44
Cyclophilin inhibitors in hepatitis C viral infection
Flisiak, R., Dumont, J., & Crabbé, R. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.9.1345 · Cited by 44
Choi, Y. H., Kang, H.-S., & Yoo, M. (2003) · BMB Reports · doi:10.5483/bmbrep.2003.36.2.223 · Cited by 43
Predicting Bevirimat resistance of HIV-1 from genotype
Heider, D., Verheyen, J., & Hoffmann, D. E. (2010) · BMC Bioinformatics · doi:10.1186/1471-2105-11-37 · Cited by 42
Treatment of Streptozotocin-Induced Diabetic Rats With AVE7688, a Vasopeptidase Inhibitor
Davidson, E. P., Kleinschmidt, T. L., Oltman, C. L., Lund, D. D., & Yorek, M. A. (2007) · Diabetes · doi:10.2337/db06-1180 · Cited by 42
Brossi, A., PEI, X. ‐., & Greig, N. (1996) · Australian Journal of Chemistry · doi:10.1071/ch9960171 · Cited by 41
Escargueil, A. E., Poindessous, V., Soares, D. G., Sarasin, A. R., Cook, P. R., & Larsen, A. K. (2008) · Journal of Cell Science · doi:10.1242/jcs.023259 · Cited by 40
METABOLIC PROFILE OF 1,5-DICAFFEOYLQUINIC ACID IN RATS, AN IN VIVO AND IN VITRO STUDY
Yang, B., Meng, Z., Dong, J.-X., Yan, L., Zou, L., Tang, Z.-M., & Dou, G. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.002154 · Cited by 39
Development potential of rifalazil and other benzoxazinorifamycins
Rothstein, D. M., Shalish, C., Murphy, C. K., Sternlicht, A. L., & Campbell, L. A. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.6.603 · Cited by 38
Ramanathan, R. K., Picus, J., Raftopoulos, H., Bernard, S. A., Lockhart, A. C., Frenette, G., Macdonald, J. S., Melin, S. A., Berg, D., Brescia, F., et al. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0489-5 · Cited by 37
Widmer, A. F. (2008) · Clinical Infectious Diseases · doi:10.1086/526528 · Cited by 37
Jacobs, M. R. (2007) · Future Microbiology · doi:10.2217/17460913.2.6.591 · Cited by 37
Noser, J. A., Towers, G. J., Sakuma, R., Dumont, J., Collins, M. K., & Ikeda, Y. (2006) · Journal of Virology · doi:10.1128/jvi.02427-05 · Cited by 36
Next-generation calcineurin inhibitors for ophthalmic indications
Anglade, E., Yatscoff, R. W., Foster, R. T., & Grau, U. M. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.10.1525 · Cited by 36
Kluza, J., Mazinghien, R., Irwin, H., Hartley, J. A., & Bailly, C. (2006) · Anti-Cancer Drugs · doi:10.1097/00001813-200602000-00006 · Cited by 35
Makarov, A. А., Tsvetkov, P. O., Villard, C., Esquieu, D., Pourroy, B., Fahy, J., Braguer, D., Peyrot, V., & Lafitte, D. (2007) · Biochemistry · doi:10.1021/bi701803s · Cited by 35
Levels of p27kip1 determine Aplidin sensitivity
Moneo, V., Serelde, B. G., Martínez-Leal, J. F., Blanco‐Aparicio, C., Díaz‐Uriarte, R., Aracil, M., Tercero, J. C., Jimeno, J. M., & Carnero, A. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0729 · Cited by 34
Zhanel, G. G., Hisanaga, T., Nichol, K. A., Wierzbowski, A. K., & Hoban, D. J. (2003) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.8.2.297 · Cited by 32
López, R., Goodman, A. B., Rhodes, M., Blomberg, J. A. L., & Heller, J. (2007) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32813148e0 · Cited by 31
Anidulafungin: a new echinocandin for candidal infections
de la Torre, P., & Reboli, A. C. (2007) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.5.1.45 · Cited by 31
Diflomotecan, a promising homocamptothecin for cancer therapy
Kroep, J. R., & Gelderblom, H. A. J. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780802571674 · Cited by 31
Sargent, J. M., Elgie, A. W., Williamson, C. J., & Hill, B. T. (2003) · Anti-Cancer Drugs · doi:10.1097/00001813-200307000-00013 · Cited by 31
Gu, R., Dou, G., Wang, J., Dong, J.-X., & Meng, Z. (2007) · Journal of Chromatography B · doi:10.1016/j.jchromb.2006.12.055 · Cited by 30
Isaacson, R. E. (2003) · PubMed · Cited by 30
Irofulven induces replication-dependent CHK2 activation related to p53 status
Wang, Y., Wiltshire, T. D., Senft, J., Reed, E., & Wang, W. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.10.023 · Cited by 28
Zheng, F., Zheng, G., Deaciuc, A. G., Zhan, C., Dwoskin, L. P., & Crooks, P. A. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.02.013 · Cited by 28
Brzankalski, G. E., Najvar, L. K., Wiederhold, N. P., Bocanegra, R. A., Fothergill, A. W., Rinaldi, M. G., Pattterson, T. F., & Graybill, J. R. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn304 · Cited by 28
New Therapeutic Options for Chemotherapy-Resistant Metastatic Breast Cancer: The Epothilones
Pronzato, P. (2008) · Drugs · doi:10.2165/00003495-200868020-00001 · Cited by 27
Revill, P., Mealy, N., Serradell, N., Bolos, J., & Rosa, E. (2007) · Drugs of the Future · doi:10.1358/dof.2007.032.04.1094476 · Cited by 27
Lisdexamfetamine: A prodrug for the treatment of attention-deficit/hyperactivity disorder
Popovic, B., Bhattacharya, P., & Sivaswamy, L. (2009) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp080353 · Cited by 24
Ferrari, P., Ferrandi, M., Valentini, G., Manunta, P., & Bianchi, G. (2006) · Medical Hypotheses · doi:10.1016/j.mehy.2006.07.058 · Cited by 24
Succinylcholine or rocuronium? A meta-analysis of the effects on intubation conditions
Karcıoğlu, Ö., Arnold, J. L., Topaçoğlu, H., Özüçelik, D. N., Kıran, S., & SONMEZ, N. (2006) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2005.00685.x · Cited by 24
Antipropionibacterial Activity of BAL19403, a Novel Macrolide Antibiotic
Heller, S., Kellenberger, L., & Shapiro, S. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00062-07 · Cited by 22
OASIS-HT: Design of a Pharmacogenomic Dose-Finding Study
Staessen, J. A., Kuznetsova, T., Accetto, R., Bacchieri, A., Brand, E., Burnier, M., Celis, H., Citterio, L., de Leeuw, P. W., Filipovský, J., et al. (2005) · Pharmacogenomics · doi:10.2217/14622416.6.7.755 · Cited by 19
Gyermek, L. (2005) · Medicinal Research Reviews · doi:10.1002/med.20036 · Cited by 19
Rifalazil and Other Benzoxazinorifamycins in the Treatment of Chlamydia‐Based Persistent Infections
Rothstein, D. M., van Duzer, J., Sternlicht, A. L., & Gilman, S. C. (2007) · Archiv der Pharmazie · doi:10.1002/ardp.200700080 · Cited by 18
Watanabe, J., Natsume, T., & Kobayashi, M. (2007) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e3280dce1d1 · Cited by 18
Wind, M., Gebhardt, K., Grunwald, H., Spickermann, J., Donzelli, M., Kellenberger, L., Muller, M., Fullhardt, P., Schmitt‐Hoffmann, A. H., & Schleimer, M. (2007) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.2926 · Cited by 16
Kakeya, H., Miyazaki, Y., Senda, H., Kobayashi, T., Seki, M., Izumikawa, K., Yanagihara, K., Yamamoto, Y., Tashiro, T., & Kohno, S. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01369-07 · Cited by 16
Kobierski, L. A., Abdi, S., Dilorenzo, L., Feroz, N., & Borsook, D. (2003) · Anesthesia & Analgesia · doi:10.1213/01.ane.0000066359.83348.f1 · Cited by 13
Stucki, A., Gerber, P. A., Acosta, F., Cottagnoud, M., Cottagnoud, P., Jiang, L., Nguyen, P., Wachtel, D., Wang, G., & Phan, L. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm505 · Cited by 13
Chernova, M. N., Vandorpe, D. H., Clark, J. S., Williams, J. I., ZASLOFF, M. A., Jiang, L., & Alper, S. L. (2005) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00098.2005 · Cited by 10
Dulsat, C., & Mealy, N. (2009) · Drugs of the Future · doi:10.1358/dof.2009.034.01.1323946 · Cited by 10
du Bois, A., Jung, B., Loehr, A., Schaller-Kranz, T., Cohen, M., & Frickhofen, N. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602886 · Cited by 9
Revill, P. A., Serradell, N., & Bolos, J. (2006) · Drugs of the Future · doi:10.1358/dof.2006.031.06.1000709 · Cited by 6
Cited by
The re-emergence of natural products for drug discovery in the genomics era
Harvey, A. L., Edrada-Ebel, R., & Quinn, R. J. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4510 · Cited by 2,572
A Historical Overview of Natural Products in Drug Discovery
Dias, D. A., Urban, S., & Roessner, U. (2012) · Metabolites · doi:10.3390/metabo2020303 · Cited by 1,958
Counting on natural products for drug design
Rodrigues, T., Reker, D., Schneider, P., & Schneider, G. (2016) · Nature Chemistry · doi:10.1038/nchem.2479 · Cited by 1,250
Cu-Catalyzed Click Reaction in Carbohydrate Chemistry
Tiwari, V. K., Mishra, B. B., Mishra, K. B., Mishra, N., Singh, A. S., & Chen, X. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00408 · Cited by 862
Self-citationSeca, A., & Pinto, D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19010263 · Cited by 686
Metadata
- Authors
- Mishra, B. B., & Tiwari, V. K.
- Venue
- European Journal of Medicinal Chemistry
- Publisher
- Elsevier BV
- Published
- 2011-10
- Volume
- 46
- Issue
- 10
- Pages
- 4769-4807
- ISSN
- 0223-5234 (ISSN-L)
- OpenAlex
- W1982728268
- Cited by
- 860
- References
- 316
- FWCI
- 32.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.